1
|
Mukherjee T, Tung KS, Jena P, Goswami C, Chattopadhyay S. Upregulation, Functional Association, and Correlated Expressions of TRPV1 and TRPA1 During Telmisartan-Driven Immunosuppression of T Cells. Immunol Invest 2024; 53:622-639. [PMID: 38584464 DOI: 10.1080/08820139.2024.2329203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2024]
Abstract
TRPV1 and TRPA1, are known to be functionally expressed in T cells, where these two channels differentially regulate effector immune responses. Telmisartan (TM), an anti-hypertension drug, has been recently repurposed to suppress various inflammatory responses. However, the possible involvement of TRP channels during TM-driven suppression of T cells responses has not been explored yet. In this study, we investigated the potential role of TRPV1 and TRPA1 during TM-driven immunosuppression of T cells in vitro. We observed a significant elevation of both TRPV1 and TRPA1 during TM-induced immunosuppression of T cells.We found that TRPA1 activation-driven suppression of T cell activation and effector cytokine responses during TM treatment is partially, yet significantly overridden by TRPV1 activation. Moreover, the expressions of TRPV1 and TRPA1 were highly correlated in various conditions of T cell. Mechanistically, it might be suggested that TRPV1 and TRPA1 are differentially involved in regulating T cell activation despite the co-elevation of both these TRP channels' expressions in the presence of TM. T cell activation was delineated by CD69 and CD25 expressions along with the effector cytokine levels (IFN-γ and TNF) in TM-driven suppression of T cell. These findings could have broad implications for designing possible future immunotherapeutic strategies, especially in the repurposing of TM for T cell-TRP-directed immune disorders.
Collapse
Affiliation(s)
- Tathagata Mukherjee
- School of Biological Sciences, National Institute of Science Education and Research (NISER), Jatni, India
| | - Kshyama Subhadarsini Tung
- School of Biological Sciences, National Institute of Science Education and Research (NISER), Jatni, India
| | - Parthasarathi Jena
- School of Biological Sciences, National Institute of Science Education and Research (NISER), Jatni, India
| | - Chandan Goswami
- School of Biological Sciences, National Institute of Science Education and Research (NISER), Jatni, India
| | - Subhasis Chattopadhyay
- School of Biological Sciences, National Institute of Science Education and Research (NISER), Jatni, India
| |
Collapse
|
2
|
Diego L, Jazmin F, Diana R, German‐Isauro G, Salvador F, Maria‐Elena H. Modulation of TNF-α, interleukin-6, and interleukin-10 by nebivolol-valsartan and nebivolol-lisinopril polytherapy in SHR rats. Pharmacol Res Perspect 2024; 12:e1189. [PMID: 38504425 PMCID: PMC10951418 DOI: 10.1002/prp2.1189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 03/04/2024] [Accepted: 03/05/2024] [Indexed: 03/21/2024] Open
Abstract
Antihypertensive drug therapies have demonstrated their capacity to modulate the inflammatory processes associated with hypertension, leading to improvements in disease progression. Given the prevalent use of polytherapy in treating most hypertensive patients, comprehending the time-dependent effects of combination treatments on inflammation becomes imperative. In this study, spontaneously hypertensive rats (SHR) were divided into seven groups (n = 6): (i) SHR + vehicle, (ii) SHR + nebivolol, (iii) SHR + valsartan, (iv) SHR + lisinopril, (v) SHR + nebivolol-valsartan, (vi) SHR + nebivolol-lisinopril, and (vii) WKY + vehicle. Blood pressure was measured using the tail-cuff method. Temporal alterations in inflammatory cytokines TNF-α, IL-6, and IL-10 were assessed in serum through ELISA and mRNA expression in aortic tissue via qPCR after 1, 2, and 4 weeks of treatment with nebivolol, lisinopril, valsartan, and their respective combinations. Histological alterations in the aorta were assessed. The findings indicated that combined treatments reduced systolic and diastolic blood pressure in SHR. The nebivolol and lisinopril combination demonstrated a significant decrease in IL-6 serum and mRNA expression at both 1 week and 4 weeks into the treatment. Additionally, TNF-α mRNA expression also showed a reduction with this combination at the same time points. Particularly, nebivolol-valsartan significantly decreased TNF-α serum and mRNA expression after one and four weeks of treatment. Furthermore, an elevation in serum IL-10 levels was observed with both combination treatments starting from the second week onwards. This study provides compelling evidence that concurrent administration of nebivolol with lisinopril or valsartan exerts time-dependent effects, reducing proinflammatory cytokines TNF-α and IL-6 while modifying IL-10 levels in an experimental hypertensive model.
Collapse
Affiliation(s)
- Lezama‐Martinez Diego
- Laboratory of Pharmacology, FES CuautitlanUniversidad Nacional Autonoma de MexicoCuautitlan IzcalliMexicoMexico
| | - Flores‐Monroy Jazmin
- Laboratory of Pharmacology, FES CuautitlanUniversidad Nacional Autonoma de MexicoCuautitlan IzcalliMexicoMexico
| | - Ramirez‐Hernandez Diana
- Laboratory of Pharmacology, FES CuautitlanUniversidad Nacional Autonoma de MexicoCuautitlan IzcalliMexicoMexico
| | | | - Fonseca‐Coronado Salvador
- Laboratory of Pharmacology, FES CuautitlanUniversidad Nacional Autonoma de MexicoCuautitlan IzcalliMexicoMexico
| | - Hernandez‐Campos Maria‐Elena
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de MedicinaInstituto Politecnico NacionalFederal DistrictMexicoMexico
| |
Collapse
|
4
|
Batista ES, da Silva Rios T, Muñoz VR, Jesus JS, Vasconcelos MM, da Cunha DT, Marques-Rocha JL, Nakandakari SCBR, Lara R, da Silva ASR, Pauli JR, Ropelle ER, Mekary RA, de Moura LP, Camargo EA, Cintra DE. Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the "Brazilian Omega Study" (BROS)-a randomized controlled trial. Trials 2021; 22:927. [PMID: 34922604 PMCID: PMC8684080 DOI: 10.1186/s13063-021-05702-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 10/08/2021] [Indexed: 12/03/2022] Open
Abstract
Abstract The low-grade inflammation is pivotal in obesity and its comorbidities; however, the inflammatory proteins are out of target for traditional drug therapy. Omega-3 (ω3) fatty acids can modulate the downstream signaling of Toll-like receptor (TLR) and tumor necrosis factor-α receptor (TNFα) through GPR120, a G-protein-coupled receptor, a mechanism not yet elucidated in humans. This work aims to investigate if the ω3 supplementation, at a feasible level below the previously recommended level in the literature, is enough to disrupt the inflammation and endoplasmic reticulum stress (ER-stress), and also if in acute treatment (3 h) ω3 can activate the GPR120 in peripheral blood mononuclear cells (PBMC) and leukocytes from overweight non-alcoholic fatty liver disease (NAFLD) participants. The R270H variant of the Ffar4 (GPR120 gene) will also be explored about molecular responses and blood lipid profiles. A triple-blind, prospective clinical trial will be conducted in overweight men and women, aged 19–75 years, randomized into placebo or supplemented (2.2 g of ω3 [EPA+DHA]) groups for 28 days. For sample calculation, it was considered the variation of TNFα protein and a 40% dropout rate, obtaining 22 individuals in each group. Volunteers will be recruited among patients with NAFLD diagnosis. Anthropometric parameters, food intake, physical activity, total serum lipids, complete fatty acid blood profile, and glycemia will be evaluated pre- and post-supplementation. In the PBMC and neutrophils, the protein content and gene expression of markers related to inflammation (TNFα, MCP1, IL1β, IL6, IL10, JNK, and TAK1), ER-stress (ATF1, ATF6, IRE1, XBP1, CHOP, eIF2α, eIF4, HSP), and ω3 pathway (GPR120, β-arrestin2, Tab1/2, and TAK1) will be evaluated using Western blot and RT-qPCR. Participants will be genotyped for the R270H (rs116454156) variant using the TaqMan assay. It is hypothesized that attenuation of inflammation and ER-stress signaling pathways in overweight and NAFLD participants will be achieved through ω3 supplementation through binding to the GPR120 receptor. Trial registration ClinicalTrials.gov #RBR-7x8tbx. Registered on May 10, 2018, with the Brazilian Registry of Clinical Trials. Supplementary Information The online version contains supplementary material available at 10.1186/s13063-021-05702-x.
Collapse
Affiliation(s)
- Ellencristina Silva Batista
- Graduate Program of Health Sciences (PPGCS), Federal University of Sergipe, Aracaju, Sergipe, Brazil.,Laboratory of Nutritional Genomics, School of Applied Sciences, University of Campinas, Pedro Zaccaria, 1300 Zip, Limeira, 13484-350, Brazil.,Nutrition Department, Federal University of Sergipe, Lagarto, Sergipe, Brazil.,Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Thaiane da Silva Rios
- Laboratory of Nutritional Genomics, School of Applied Sciences, University of Campinas, Pedro Zaccaria, 1300 Zip, Limeira, 13484-350, Brazil.,Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Vitor Rosetto Muñoz
- Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil.,Laboratory of Molecular Biology of Exercise, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Joyce Santos Jesus
- Nutrition Department, Federal University of Sergipe, Lagarto, Sergipe, Brazil
| | | | - Diogo Thimóteo da Cunha
- Multidisciplinary Laboratory of Food and Health, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Jose Luis Marques-Rocha
- Department of Integrated Health Education, Federal University of Espírito Santo, Vitoria, Brazil
| | - Susana Castelo Branco Ramos Nakandakari
- Laboratory of Nutritional Genomics, School of Applied Sciences, University of Campinas, Pedro Zaccaria, 1300 Zip, Limeira, 13484-350, Brazil.,Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Roberta Lara
- Laboratory of Nutritional Genomics, School of Applied Sciences, University of Campinas, Pedro Zaccaria, 1300 Zip, Limeira, 13484-350, Brazil
| | - Adelino Sanchez Ramos da Silva
- School of Physical Education and Sport of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo, Brazil
| | - José Rodrigo Pauli
- Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil.,Laboratory of Molecular Biology of Exercise, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Eduardo Rochete Ropelle
- Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil.,Laboratory of Molecular Biology of Exercise, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | - Rania Angelina Mekary
- Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, USA.,Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Leandro Pereira de Moura
- Laboratory of Molecular Biology of Exercise, School of Applied Sciences, University of Campinas, Limeira, Brazil
| | | | - Dennys Esper Cintra
- Laboratory of Nutritional Genomics, School of Applied Sciences, University of Campinas, Pedro Zaccaria, 1300 Zip, Limeira, 13484-350, Brazil. .,Lipids and Nutrigenomics Research Center, School of Applied Sciences, University of Campinas, Limeira, Brazil.
| |
Collapse
|
5
|
Ranadive SM, Dillon GA, Mascone SE, Alexander LM. Vascular Health Triad in Humans With Hypertension-Not the Usual Suspects. Front Physiol 2021; 12:746278. [PMID: 34658930 PMCID: PMC8517241 DOI: 10.3389/fphys.2021.746278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 08/25/2021] [Indexed: 11/13/2022] Open
Abstract
Hypertension (HTN) affects more than one-third of the US population and remains the top risk factor for the development of cardiovascular disease (CVD). Identifying the underlying mechanisms for developing HTN are of critical importance because the risk of developing CVD doubles with ∼20 mmHg increase in systolic blood pressure (BP). Endothelial dysfunction, especially in the resistance arteries, is the primary site for initiation of sub-clinical HTN. Furthermore, inflammation and reactive oxygen and nitrogen species (ROS/RNS) not only influence the endothelium independently, but also have a synergistic influence on each other. Together, the interplay between inflammation, ROS and vascular dysfunction is referred to as the vascular health triad, and affects BP regulation in humans. While the interplay of the vascular health triad is well established, new underlying mechanistic targets are under investigation, including: Inducible nitric oxide synthase, hydrogen peroxide, hydrogen sulfide, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and nuclear factor activated T cells. This review outlines the role of these unusual suspects in vascular health and function in humans. This review connects the dots using these unusual suspects underlying inflammation, ROS and vascular dysfunction especially in individuals at risk of or with diagnosed HTN based on novel studies performed in humans.
Collapse
Affiliation(s)
- Sushant M Ranadive
- Department of Kinesiology, University of Maryland, College Park, College Park, MD, United States
| | - Gabrielle A Dillon
- Department of Kinesiology, The Pennsylvania State University, University Park, PA, United States.,Center for Healthy Aging, The Pennsylvania State University, University Park, PA, United States
| | - Sara E Mascone
- Department of Kinesiology, University of Maryland, College Park, College Park, MD, United States
| | - Lacy M Alexander
- Department of Kinesiology, The Pennsylvania State University, University Park, PA, United States.,Center for Healthy Aging, The Pennsylvania State University, University Park, PA, United States
| |
Collapse
|